Ophthalmic Drugs Market Size, Share, By Product Type (Prescription Drugs and Over The Counter Drugs), Drug Type (Branded Drugs and Generic Drugs), Disease Indication (Dry Eye, Glaucoma, Infection/Inflammation, Retinal Disorders, and Others), Route of Administration (Topical, Local Ocular, and Systemic), Dosage Form (Gels, Eye Solutions and Suspension, Capsules and Tablets, Eye Drops, and Others), Therapeutic Class (Anti-inflammatory Drugs, Anti-infective Drugs, Anti-glaucoma Drugs, Anti-allergy Drugs, Anti-VEGF Agents, and Others), Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Independent Pharmacies and Others), and Region - Trends, Analysis, and Forecast till 2035

Among the major companies in the market are Pfizer Inc., Bausch + Lomb, Alcon Inc., and others.  These major companies are concentrating on cutting-edge drug delivery methods, focused treatments, and specialist fields, utilizing gene therapy breakthroughs, halting the emergence of age-related eye disorders, and broadening distribution networks in order to propel the expansion of the ophthalmic drugs market.

List of Key Players in the Market:

• Alcon Inc.
• Bausch + Lomb
• Pfizer Inc.
• Sun Pharmaceutical Industries, Inc.
• F. Hoffmann-La Roche Ltd
• Grevis Pharmaceuticals Pvt Ltd.
• Eyeris Vision Care Pvt. Ltd.
• Santen Pharmaceutical Co., Ltd.
• Genentech USA, Inc.
• Coherus BioSciences, Inc.
• Johnson & Johnson
• Teva Pharmaceutical Industries Ltd.
• Harrow
• Ocular Therapeutix, Inc.
• EyePoint Pharmaceuticals, Inc.

Recent News:

• Glenmark Pharmaceuticals Inc. USA had launched Latanoprost Ophthalmic Solution, a 0.005% (0.05 mg/mL) ophthalmic solution, in February 2025. This product was bioequivalent and therapeutically equivalent to the reference listed drug, Xalatan Ophthalmic Solution. This addition highlighted the company’s commitment to meeting market needs and providing quality solutions for its customers.
• Viatris Inc., a global healthcare company, announced the U.S. commercial launch of RYZUMVI (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents in the United States, in April 2024.  RYZUMVI was the only U.S. commercially available FDA-approved eye drop to reverse dilation.
• Amneal Pharmaceuticals, Inc. announced the approval and launch of fluorometholone ophthalmic suspension, in January 2024. The product received 180-day competitive generic therapy (CGT) exclusivity from the U.S. Food and Drug Administration, a status that applied to first-marketed generics of key medicines. FML suspension was indicated for the treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.
• Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on reshaping vision possibilities, announced that the U.S. Food and Drug Administration (FDA) had approved QLOSI (pilocarpine hydrochloride ophthalmic solution) 0.4% for the treatment of presbyopia in adults, in October 2023. QLOSI was expected to be commercially available in the U.S. in the first half of 2024.
• Teva Pharmaceuticals USA, Inc., announced its launch of the first available generic version of AZOPT (brinzolamide ophthalmic suspension) 1%, approved by the US Food and Drug Administration to treat high pressure inside the eye due to ocular hypertension and open-angle glaucoma, in March 2021. Brinzolamide ophthalmic suspension 1% worked by decreasing the amount of fluid within the eye.